{"entity":{"type":"insider","cik":"0001353128","url":"/insider/0001353128","json_url":"/insider/0001353128.json","name":"Duncan Barbara Gayle","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":53,"n_filings":22,"first":"2013-05-22","last":"2020-09-16","span_basis":"filed_date"},"name_variants":[{"name":"Duncan Barbara Gayle","source":"filing","n_filings":22,"first_seen":"2013-05-22","last_seen":"2020-09-16"}],"transactions":[{"id":3266938,"accession":"0001640455-20-000116","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001640455-20-000116","line_url":"/filing/0001640455-20-000116#line-3","is_derivative":false,"issuer_cik":"0001353128","issuer_name":"Jounce Therapeutics, Inc.","issuer_ticker":"JNCE","issuer_name_source":null,"issuer_url":"/issuer/0001353128","owner_cik":"0001353128","owner_name":"Duncan Barbara Gayle","owner_url":"/insider/0001353128","role":"Director","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5000.0,"shares_display":"5,000","price_per_share":10.5,"price_display":"10.50","price_state":"stated","total_value":52500.0,"total_display":"52,500.00","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-09-15","filed_date":"2020-09-16","scope":"insider"},{"id":3266935,"accession":"0001640455-20-000116","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001640455-20-000116","line_url":"/filing/0001640455-20-000116#line-2","is_derivative":false,"issuer_cik":"0001353128","issuer_name":"Jounce Therapeutics, Inc.","issuer_ticker":"JNCE","issuer_name_source":null,"issuer_url":"/issuer/0001353128","owner_cik":"0001353128","owner_name":"Duncan Barbara Gayle","owner_url":"/insider/0001353128","role":"Director","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5000.0,"shares_display":"5,000","price_per_share":9.5,"price_display":"9.50","price_state":"stated","total_value":47500.0,"total_display":"47,500.00","shares_owned_after":5000.0,"shares_owned_after_display":"5,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-09-15","filed_date":"2020-09-16","scope":"insider"},{"id":6319771,"accession":"0001640455-18-000043","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001640455-18-000043","line_url":"/filing/0001640455-18-000043#line-2","is_derivative":false,"issuer_cik":"0001353128","issuer_name":"Jounce Therapeutics, Inc.","issuer_ticker":"JNCE","issuer_name_source":null,"issuer_url":"/issuer/0001353128","owner_cik":"0001353128","owner_name":"Duncan Barbara Gayle","owner_url":"/insider/0001353128","role":"Director","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2000.0,"shares_display":"2,000","price_per_share":28.11,"price_display":"28.11","price_state":"stated","total_value":56220.0,"total_display":"56,220.00","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-03-15","filed_date":"2018-03-19","scope":"insider"},{"id":6170706,"accession":"0001640455-18-000007","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001640455-18-000007","line_url":"/filing/0001640455-18-000007#line-2","is_derivative":false,"issuer_cik":"0001353128","issuer_name":"Jounce Therapeutics, Inc.","issuer_ticker":"JNCE","issuer_name_source":null,"issuer_url":"/issuer/0001353128","owner_cik":"0001353128","owner_name":"Duncan Barbara Gayle","owner_url":"/insider/0001353128","role":"Director","officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4000.0,"shares_display":"4,000","price_per_share":25.0,"price_display":"25.00","price_state":"stated","total_value":100000.0,"total_display":"100,000.00","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-01-26","filed_date":"2018-01-29","scope":"insider"},{"id":4754224,"accession":"0001144204-17-053029","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001144204-17-053029","line_url":"/filing/0001144204-17-053029#line-1","is_derivative":false,"issuer_cik":"0001138776","issuer_name":"Aevi Genomic Medicine, Inc.","issuer_ticker":"GNMX","issuer_name_source":null,"issuer_url":"/issuer/0001138776","owner_cik":"0001353128","owner_name":"Duncan Barbara Gayle","owner_url":"/insider/0001353128","role":"Director","officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":59524.0,"shares_display":"59,524","price_per_share":1.26,"price_display":"1.26","price_state":"stated","total_value":75000.24,"total_display":"75,000.24","shares_owned_after":59524.0,"shares_owned_after_display":"59,524","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-10-17","filed_date":"2017-10-18","scope":"insider"},{"id":2844679,"accession":"0001144204-16-127097","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001144204-16-127097","line_url":"/filing/0001144204-16-127097#line-1","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001353128","owner_name":"Duncan Barbara Gayle","owner_url":"/insider/0001353128","role":"Officer (Chief Accounting Officer)","officer_title":"Chief Accounting Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":147.0,"shares_display":"147","price_per_share":163.1997,"price_display":"163.20","price_state":"stated","total_value":23990.3559,"total_display":"23,990.36","shares_owned_after":30661.0,"shares_owned_after_display":"30,661","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-10-03","filed_date":"2016-10-05","scope":"insider"},{"id":2197038,"accession":"0001144204-16-112101","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001144204-16-112101","line_url":"/filing/0001144204-16-112101#line-1","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001353128","owner_name":"Duncan Barbara Gayle","owner_url":"/insider/0001353128","role":"Officer (Chief Accounting Officer)","officer_title":"Chief Accounting Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":146.0,"shares_display":"146","price_per_share":145.1092,"price_display":"145.11","price_state":"stated","total_value":21185.9432,"total_display":"21,185.94","shares_owned_after":30808.0,"shares_owned_after_display":"30,808","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-07-05","filed_date":"2016-07-07","scope":"insider"},{"id":2172748,"accession":"0001144204-16-093108","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001144204-16-093108","line_url":"/filing/0001144204-16-093108#line-1","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001353128","owner_name":"Duncan Barbara Gayle","owner_url":"/insider/0001353128","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":144.0,"shares_display":"144","price_per_share":130.76,"price_display":"130.76","price_state":"stated","total_value":18829.44,"total_display":"18,829.44","shares_owned_after":30948.0,"shares_owned_after_display":"30,948","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-04-04","filed_date":"2016-04-06","scope":"insider"},{"id":2387419,"accession":"0001144204-16-074239","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001144204-16-074239","line_url":"/filing/0001144204-16-074239#line-3","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001353128","owner_name":"Duncan Barbara Gayle","owner_url":"/insider/0001353128","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":428.0,"shares_display":"428","price_per_share":145.9037,"price_display":"145.90","price_state":"stated","total_value":62446.7836,"total_display":"62,446.78","shares_owned_after":24892.0,"shares_owned_after_display":"24,892","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-01-04","filed_date":"2016-01-05","scope":"insider"},{"id":2387412,"accession":"0001144204-16-074239","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001144204-16-074239","line_url":"/filing/0001144204-16-074239#line-2","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001353128","owner_name":"Duncan Barbara Gayle","owner_url":"/insider/0001353128","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":40.0,"shares_display":"40","price_per_share":145.9037,"price_display":"145.90","price_state":"stated","total_value":5836.148,"total_display":"5,836.15","shares_owned_after":25320.0,"shares_owned_after_display":"25,320","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-01-04","filed_date":"2016-01-05","scope":"insider"},{"id":8930628,"accession":"0001144204-15-058166","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001144204-15-058166","line_url":"/filing/0001144204-15-058166#line-5","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001353128","owner_name":"Duncan Barbara Gayle","owner_url":"/insider/0001353128","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":54.0,"shares_display":"54","price_per_share":159.0393,"price_display":"159.04","price_state":"stated","total_value":8588.1222,"total_display":"8,588.12","shares_owned_after":24062.0,"shares_owned_after_display":"24,062","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-10-02","filed_date":"2015-10-05","scope":"insider"},{"id":8930627,"accession":"0001144204-15-058166","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001144204-15-058166","line_url":"/filing/0001144204-15-058166#line-4","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001353128","owner_name":"Duncan Barbara Gayle","owner_url":"/insider/0001353128","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1000.0,"shares_display":"1,000","price_per_share":163.39,"price_display":"163.39","price_state":"stated","total_value":163390.0,"total_display":"163,390.00","shares_owned_after":24116.0,"shares_owned_after_display":"24,116","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-10-01","filed_date":"2015-10-05","scope":"insider"},{"id":8822244,"accession":"0001144204-15-041464","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001144204-15-041464","line_url":"/filing/0001144204-15-041464#line-4","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001353128","owner_name":"Duncan Barbara Gayle","owner_url":"/insider/0001353128","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":50.0,"shares_display":"50","price_per_share":236.13,"price_display":"236.13","price_state":"stated","total_value":11806.5,"total_display":"11,806.50","shares_owned_after":18771.0,"shares_owned_after_display":"18,771","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-07-02","filed_date":"2015-07-07","scope":"insider"},{"id":8822243,"accession":"0001144204-15-041464","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001144204-15-041464","line_url":"/filing/0001144204-15-041464#line-3","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001353128","owner_name":"Duncan Barbara Gayle","owner_url":"/insider/0001353128","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2.0,"shares_display":"2","price_per_share":238.1601,"price_display":"238.16","price_state":"stated","total_value":476.3202,"total_display":"476.32","shares_owned_after":18769.0,"shares_owned_after_display":"18,769","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-07-02","filed_date":"2015-07-07","scope":"insider"},{"id":8822241,"accession":"0001144204-15-041464","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001144204-15-041464","line_url":"/filing/0001144204-15-041464#line-2","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001353128","owner_name":"Duncan Barbara Gayle","owner_url":"/insider/0001353128","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1.0,"shares_display":"1","price_per_share":239.0001,"price_display":"239.00","price_state":"stated","total_value":239.0001,"total_display":"239.00","shares_owned_after":18768.0,"shares_owned_after_display":"18,768","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-07-02","filed_date":"2015-07-07","scope":"insider"},{"id":8527646,"accession":"0001144204-15-041254","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001144204-15-041254","line_url":"/filing/0001144204-15-041254#line-2","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001353128","owner_name":"Duncan Barbara Gayle","owner_url":"/insider/0001353128","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1000.0,"shares_display":"1,000","price_per_share":242.1,"price_display":"242.10","price_state":"stated","total_value":242100.0,"total_display":"242,100.00","shares_owned_after":17523.0,"shares_owned_after_display":"17,523","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-07-01","filed_date":"2015-07-06","scope":"insider"},{"id":8071092,"accession":"0001144204-15-021236","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001144204-15-021236","line_url":"/filing/0001144204-15-021236#line-2","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001353128","owner_name":"Duncan Barbara Gayle","owner_url":"/insider/0001353128","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":39.0,"shares_display":"39","price_per_share":277.7006,"price_display":"277.70","price_state":"stated","total_value":10830.3234,"total_display":"10,830.32","shares_owned_after":17523.0,"shares_owned_after_display":"17,523","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-04-02","filed_date":"2015-04-03","scope":"insider"},{"id":8500988,"accession":"0001144204-15-020400","txn_seq":8,"anchor":"line-8","filing_url":"/filing/0001144204-15-020400","line_url":"/filing/0001144204-15-020400#line-8","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001353128","owner_name":"Duncan Barbara Gayle","owner_url":"/insider/0001353128","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":300.0,"shares_display":"300","price_per_share":293.3375,"price_display":"293.34","price_state":"stated","total_value":88001.25,"total_display":"88,001.25","shares_owned_after":16264.0,"shares_owned_after_display":"16,264","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-03-27","filed_date":"2015-04-01","scope":"insider"},{"id":8500981,"accession":"0001144204-15-020400","txn_seq":7,"anchor":"line-7","filing_url":"/filing/0001144204-15-020400","line_url":"/filing/0001144204-15-020400#line-7","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001353128","owner_name":"Duncan Barbara Gayle","owner_url":"/insider/0001353128","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":100.0,"shares_display":"100","price_per_share":292.16,"price_display":"292.16","price_state":"stated","total_value":29216.0,"total_display":"29,216.00","shares_owned_after":16564.0,"shares_owned_after_display":"16,564","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-03-27","filed_date":"2015-04-01","scope":"insider"},{"id":8500977,"accession":"0001144204-15-020400","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001144204-15-020400","line_url":"/filing/0001144204-15-020400#line-6","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001353128","owner_name":"Duncan Barbara Gayle","owner_url":"/insider/0001353128","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":100.0,"shares_display":"100","price_per_share":291.0,"price_display":"291.00","price_state":"stated","total_value":29100.0,"total_display":"29,100.00","shares_owned_after":16664.0,"shares_owned_after_display":"16,664","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-03-27","filed_date":"2015-04-01","scope":"insider"},{"id":8500973,"accession":"0001144204-15-020400","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001144204-15-020400","line_url":"/filing/0001144204-15-020400#line-5","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001353128","owner_name":"Duncan Barbara Gayle","owner_url":"/insider/0001353128","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":100.0,"shares_display":"100","price_per_share":289.0,"price_display":"289.00","price_state":"stated","total_value":28900.0,"total_display":"28,900.00","shares_owned_after":16764.0,"shares_owned_after_display":"16,764","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-03-27","filed_date":"2015-04-01","scope":"insider"},{"id":8500969,"accession":"0001144204-15-020400","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001144204-15-020400","line_url":"/filing/0001144204-15-020400#line-4","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001353128","owner_name":"Duncan Barbara Gayle","owner_url":"/insider/0001353128","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":100.0,"shares_display":"100","price_per_share":288.0,"price_display":"288.00","price_state":"stated","total_value":28800.0,"total_display":"28,800.00","shares_owned_after":16864.0,"shares_owned_after_display":"16,864","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-03-27","filed_date":"2015-04-01","scope":"insider"},{"id":8500964,"accession":"0001144204-15-020400","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001144204-15-020400","line_url":"/filing/0001144204-15-020400#line-3","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001353128","owner_name":"Duncan Barbara Gayle","owner_url":"/insider/0001353128","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":100.0,"shares_display":"100","price_per_share":287.0,"price_display":"287.00","price_state":"stated","total_value":28700.0,"total_display":"28,700.00","shares_owned_after":16964.0,"shares_owned_after_display":"16,964","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-03-27","filed_date":"2015-04-01","scope":"insider"},{"id":8500960,"accession":"0001144204-15-020400","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001144204-15-020400","line_url":"/filing/0001144204-15-020400#line-2","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001353128","owner_name":"Duncan Barbara Gayle","owner_url":"/insider/0001353128","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":100.0,"shares_display":"100","price_per_share":286.0,"price_display":"286.00","price_state":"stated","total_value":28600.0,"total_display":"28,600.00","shares_owned_after":17064.0,"shares_owned_after_display":"17,064","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-03-27","filed_date":"2015-04-01","scope":"insider"},{"id":8500955,"accession":"0001144204-15-020400","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001144204-15-020400","line_url":"/filing/0001144204-15-020400#line-1","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001353128","owner_name":"Duncan Barbara Gayle","owner_url":"/insider/0001353128","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":100.0,"shares_display":"100","price_per_share":285.0,"price_display":"285.00","price_state":"stated","total_value":28500.0,"total_display":"28,500.00","shares_owned_after":17164.0,"shares_owned_after_display":"17,164","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-03-27","filed_date":"2015-04-01","scope":"insider"},{"id":8567786,"accession":"0001144204-15-001255","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001144204-15-001255","line_url":"/filing/0001144204-15-001255#line-1","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001353128","owner_name":"Duncan Barbara Gayle","owner_url":"/insider/0001353128","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":141.0,"shares_display":"141","price_per_share":176.4857,"price_display":"176.49","price_state":"stated","total_value":24884.4837,"total_display":"24,884.48","shares_owned_after":17264.0,"shares_owned_after_display":"17,264","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-01-05","filed_date":"2015-01-07","scope":"insider"},{"id":8364455,"accession":"0001144204-15-000635","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001144204-15-000635","line_url":"/filing/0001144204-15-000635#line-4","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001353128","owner_name":"Duncan Barbara Gayle","owner_url":"/insider/0001353128","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":500.0,"shares_display":"500","price_per_share":158.3501,"price_display":"158.35","price_state":"stated","total_value":79175.05,"total_display":"79,175.05","shares_owned_after":17405.0,"shares_owned_after_display":"17,405","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-01-02","filed_date":"2015-01-05","scope":"insider"},{"id":8364452,"accession":"0001144204-15-000635","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001144204-15-000635","line_url":"/filing/0001144204-15-000635#line-3","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001353128","owner_name":"Duncan Barbara Gayle","owner_url":"/insider/0001353128","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":500.0,"shares_display":"500","price_per_share":154.45,"price_display":"154.45","price_state":"stated","total_value":77225.0,"total_display":"77,225.00","shares_owned_after":17905.0,"shares_owned_after_display":"17,905","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-01-02","filed_date":"2015-01-05","scope":"insider"},{"id":6933798,"accession":"0001144204-14-059582","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001144204-14-059582","line_url":"/filing/0001144204-14-059582#line-4","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001353128","owner_name":"Duncan Barbara Gayle","owner_url":"/insider/0001353128","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":900.0,"shares_display":"900","price_per_share":232.9244,"price_display":"232.92","price_state":"stated","total_value":209631.96,"total_display":"209,631.96","shares_owned_after":16207.0,"shares_owned_after_display":"16,207","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-10-01","filed_date":"2014-10-03","scope":"insider"},{"id":6933794,"accession":"0001144204-14-059582","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001144204-14-059582","line_url":"/filing/0001144204-14-059582#line-3","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001353128","owner_name":"Duncan Barbara Gayle","owner_url":"/insider/0001353128","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":100.0,"shares_display":"100","price_per_share":234.87,"price_display":"234.87","price_state":"stated","total_value":23487.0,"total_display":"23,487.00","shares_owned_after":16107.0,"shares_owned_after_display":"16,107","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-10-01","filed_date":"2014-10-03","scope":"insider"},{"id":7074400,"accession":"0001144204-14-022886","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001144204-14-022886","line_url":"/filing/0001144204-14-022886#line-3","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001353128","owner_name":"Duncan Barbara Gayle","owner_url":"/insider/0001353128","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1154.0,"shares_display":"1,154","price_per_share":279.0,"price_display":"279.00","price_state":"stated","total_value":321966.0,"total_display":"321,966.00","shares_owned_after":13510.0,"shares_owned_after_display":"13,510","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-04-14","filed_date":"2014-04-15","scope":"insider"},{"id":6234050,"accession":"0001144204-14-002902","txn_seq":15,"anchor":"line-15","filing_url":"/filing/0001144204-14-002902","line_url":"/filing/0001144204-14-002902#line-15","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001353128","owner_name":"Duncan Barbara Gayle","owner_url":"/insider/0001353128","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1150.0,"shares_display":"1,150","price_per_share":253.6304,"price_display":"253.63","price_state":"stated","total_value":291674.96,"total_display":"291,674.96","shares_owned_after":14883.0,"shares_owned_after_display":"14,883","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-01-15","filed_date":"2014-01-17","scope":"insider"},{"id":6234047,"accession":"0001144204-14-002902","txn_seq":14,"anchor":"line-14","filing_url":"/filing/0001144204-14-002902","line_url":"/filing/0001144204-14-002902#line-14","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001353128","owner_name":"Duncan Barbara Gayle","owner_url":"/insider/0001353128","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":750.0,"shares_display":"750","price_per_share":257.2667,"price_display":"257.27","price_state":"stated","total_value":192950.025,"total_display":"192,950.02","shares_owned_after":13133.0,"shares_owned_after_display":"13,133","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-01-15","filed_date":"2014-01-17","scope":"insider"},{"id":6234044,"accession":"0001144204-14-002902","txn_seq":13,"anchor":"line-13","filing_url":"/filing/0001144204-14-002902","line_url":"/filing/0001144204-14-002902#line-13","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001353128","owner_name":"Duncan Barbara Gayle","owner_url":"/insider/0001353128","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":500.0,"shares_display":"500","price_per_share":260.0,"price_display":"260.00","price_state":"stated","total_value":130000.0,"total_display":"130,000.00","shares_owned_after":12133.0,"shares_owned_after_display":"12,133","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-01-15","filed_date":"2014-01-17","scope":"insider"},{"id":6234040,"accession":"0001144204-14-002902","txn_seq":12,"anchor":"line-12","filing_url":"/filing/0001144204-14-002902","line_url":"/filing/0001144204-14-002902#line-12","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001353128","owner_name":"Duncan Barbara Gayle","owner_url":"/insider/0001353128","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":500.0,"shares_display":"500","price_per_share":258.3,"price_display":"258.30","price_state":"stated","total_value":129150.0,"total_display":"129,150.00","shares_owned_after":12633.0,"shares_owned_after_display":"12,633","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-01-15","filed_date":"2014-01-17","scope":"insider"},{"id":6234037,"accession":"0001144204-14-002902","txn_seq":11,"anchor":"line-11","filing_url":"/filing/0001144204-14-002902","line_url":"/filing/0001144204-14-002902#line-11","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001353128","owner_name":"Duncan Barbara Gayle","owner_url":"/insider/0001353128","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":500.0,"shares_display":"500","price_per_share":256.0,"price_display":"256.00","price_state":"stated","total_value":128000.0,"total_display":"128,000.00","shares_owned_after":13883.0,"shares_owned_after_display":"13,883","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-01-15","filed_date":"2014-01-17","scope":"insider"},{"id":6234033,"accession":"0001144204-14-002902","txn_seq":10,"anchor":"line-10","filing_url":"/filing/0001144204-14-002902","line_url":"/filing/0001144204-14-002902#line-10","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001353128","owner_name":"Duncan Barbara Gayle","owner_url":"/insider/0001353128","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":500.0,"shares_display":"500","price_per_share":255.0,"price_display":"255.00","price_state":"stated","total_value":127500.0,"total_display":"127,500.00","shares_owned_after":14383.0,"shares_owned_after_display":"14,383","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-01-15","filed_date":"2014-01-17","scope":"insider"},{"id":6234029,"accession":"0001144204-14-002902","txn_seq":9,"anchor":"line-9","filing_url":"/filing/0001144204-14-002902","line_url":"/filing/0001144204-14-002902#line-9","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001353128","owner_name":"Duncan Barbara Gayle","owner_url":"/insider/0001353128","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":300.0,"shares_display":"300","price_per_share":251.55,"price_display":"251.55","price_state":"stated","total_value":75465.0,"total_display":"75,465.00","shares_owned_after":16033.0,"shares_owned_after_display":"16,033","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-01-15","filed_date":"2014-01-17","scope":"insider"},{"id":6234026,"accession":"0001144204-14-002902","txn_seq":8,"anchor":"line-8","filing_url":"/filing/0001144204-14-002902","line_url":"/filing/0001144204-14-002902#line-8","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001353128","owner_name":"Duncan Barbara Gayle","owner_url":"/insider/0001353128","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":250.0,"shares_display":"250","price_per_share":283.9,"price_display":"283.90","price_state":"stated","total_value":70975.0,"total_display":"70,975.00","shares_owned_after":10708.0,"shares_owned_after_display":"10,708","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-01-15","filed_date":"2014-01-17","scope":"insider"},{"id":6234023,"accession":"0001144204-14-002902","txn_seq":7,"anchor":"line-7","filing_url":"/filing/0001144204-14-002902","line_url":"/filing/0001144204-14-002902#line-7","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001353128","owner_name":"Duncan Barbara Gayle","owner_url":"/insider/0001353128","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":250.0,"shares_display":"250","price_per_share":265.0,"price_display":"265.00","price_state":"stated","total_value":66250.0,"total_display":"66,250.00","shares_owned_after":11133.0,"shares_owned_after_display":"11,133","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-01-15","filed_date":"2014-01-17","scope":"insider"},{"id":6234019,"accession":"0001144204-14-002902","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001144204-14-002902","line_url":"/filing/0001144204-14-002902#line-6","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001353128","owner_name":"Duncan Barbara Gayle","owner_url":"/insider/0001353128","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":250.0,"shares_display":"250","price_per_share":264.0,"price_display":"264.00","price_state":"stated","total_value":66000.0,"total_display":"66,000.00","shares_owned_after":11383.0,"shares_owned_after_display":"11,383","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-01-15","filed_date":"2014-01-17","scope":"insider"},{"id":6234016,"accession":"0001144204-14-002902","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001144204-14-002902","line_url":"/filing/0001144204-14-002902#line-5","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001353128","owner_name":"Duncan Barbara Gayle","owner_url":"/insider/0001353128","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":250.0,"shares_display":"250","price_per_share":263.0,"price_display":"263.00","price_state":"stated","total_value":65750.0,"total_display":"65,750.00","shares_owned_after":11633.0,"shares_owned_after_display":"11,633","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-01-15","filed_date":"2014-01-17","scope":"insider"},{"id":6234012,"accession":"0001144204-14-002902","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001144204-14-002902","line_url":"/filing/0001144204-14-002902#line-4","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001353128","owner_name":"Duncan Barbara Gayle","owner_url":"/insider/0001353128","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":250.0,"shares_display":"250","price_per_share":262.0,"price_display":"262.00","price_state":"stated","total_value":65500.0,"total_display":"65,500.00","shares_owned_after":11883.0,"shares_owned_after_display":"11,883","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-01-15","filed_date":"2014-01-17","scope":"insider"},{"id":6234008,"accession":"0001144204-14-002902","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001144204-14-002902","line_url":"/filing/0001144204-14-002902#line-3","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001353128","owner_name":"Duncan Barbara Gayle","owner_url":"/insider/0001353128","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":125.0,"shares_display":"125","price_per_share":280.0,"price_display":"280.00","price_state":"stated","total_value":35000.0,"total_display":"35,000.00","shares_owned_after":10958.0,"shares_owned_after_display":"10,958","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-01-15","filed_date":"2014-01-17","scope":"insider"},{"id":6234003,"accession":"0001144204-14-002902","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001144204-14-002902","line_url":"/filing/0001144204-14-002902#line-2","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001353128","owner_name":"Duncan Barbara Gayle","owner_url":"/insider/0001353128","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":50.0,"shares_display":"50","price_per_share":274.0,"price_display":"274.00","price_state":"stated","total_value":13700.0,"total_display":"13,700.00","shares_owned_after":11083.0,"shares_owned_after_display":"11,083","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-01-15","filed_date":"2014-01-17","scope":"insider"},{"id":5248322,"accession":"0001144204-13-039039","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001144204-13-039039","line_url":"/filing/0001144204-13-039039#line-2","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001353128","owner_name":"Duncan Barbara Gayle","owner_url":"/insider/0001353128","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":25000.0,"shares_display":"25,000","price_per_share":45.3936,"price_display":"45.39","price_state":"stated","total_value":1134840.0,"total_display":"1,134,840.00","shares_owned_after":8112.0,"shares_owned_after_display":"8,112","ownership_form":"D","is_10b5_1":null,"transaction_date":"2013-07-08","filed_date":"2013-07-10","scope":"insider"},{"id":5443640,"accession":"0001144204-13-036173","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001144204-13-036173","line_url":"/filing/0001144204-13-036173#line-3","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001353128","owner_name":"Duncan Barbara Gayle","owner_url":"/insider/0001353128","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":50575.0,"shares_display":"50,575","price_per_share":34.5,"price_display":"34.50","price_state":"stated","total_value":1744837.5,"total_display":"1,744,837.50","shares_owned_after":6814.0,"shares_owned_after_display":"6,814","ownership_form":"D","is_10b5_1":null,"transaction_date":"2013-06-19","filed_date":"2013-06-21","scope":"insider"},{"id":4904356,"accession":"0001144204-13-031936","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001144204-13-031936","line_url":"/filing/0001144204-13-031936#line-6","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001353128","owner_name":"Duncan Barbara Gayle","owner_url":"/insider/0001353128","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4915.0,"shares_display":"4,915","price_per_share":34.5,"price_display":"34.50","price_state":"stated","total_value":169567.5,"total_display":"169,567.50","shares_owned_after":6814.0,"shares_owned_after_display":"6,814","ownership_form":"D","is_10b5_1":null,"transaction_date":"2013-05-28","filed_date":"2013-05-28","scope":"insider"},{"id":4904345,"accession":"0001144204-13-031936","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001144204-13-031936","line_url":"/filing/0001144204-13-031936#line-4","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001353128","owner_name":"Duncan Barbara Gayle","owner_url":"/insider/0001353128","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1200.0,"shares_display":"1,200","price_per_share":34.5,"price_display":"34.50","price_state":"stated","total_value":41400.0,"total_display":"41,400.00","shares_owned_after":6814.0,"shares_owned_after_display":"6,814","ownership_form":"D","is_10b5_1":null,"transaction_date":"2013-05-24","filed_date":"2013-05-28","scope":"insider"},{"id":4904337,"accession":"0001144204-13-031936","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001144204-13-031936","line_url":"/filing/0001144204-13-031936#line-2","is_derivative":false,"issuer_cik":"0001270073","issuer_name":"INTERCEPT PHARMACEUTICALS INC","issuer_ticker":"ICPT","issuer_name_source":null,"issuer_url":"/issuer/0001270073","owner_cik":"0001353128","owner_name":"Duncan Barbara Gayle","owner_url":"/insider/0001353128","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":110.0,"shares_display":"110","price_per_share":34.54,"price_display":"34.54","price_state":"stated","total_value":3799.4,"total_display":"3,799.40","shares_owned_after":6814.0,"shares_owned_after_display":"6,814","ownership_form":"D","is_10b5_1":null,"transaction_date":"2013-05-23","filed_date":"2013-05-28","scope":"insider"}],"next_cursor":"2013-05-23|4904337","ledger_fault":false,"count":{"value":53,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":1,"open_market":true},{"code":"S","label":"Open-market sale","n":52,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":53},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001640455","name":"Jounce Therapeutics, Inc.","url":"/issuer/0001640455","role":"Director","n_filings":3,"first_seen":"2018-01-29","last_seen":"2020-09-16"},{"type":"issuer","type_label":"ISSUER","cik":"0001138776","name":"Aevi Genomic Medicine, Inc.","url":"/issuer/0001138776","role":"Director","n_filings":1,"first_seen":"2017-10-18","last_seen":"2017-10-18"},{"type":"issuer","type_label":"ISSUER","cik":"0001270073","name":"INTERCEPT PHARMACEUTICALS INC","url":"/issuer/0001270073","role":"Officer (Chief Accounting Officer)","n_filings":18,"first_seen":"2013-05-22","last_seen":"2016-10-05"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001353128","retrieved_at":"2026-08-21T15:31:50+00:00","coverage":{"filings":1505395,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-20","last_ingest":"2026-08-21T05:23:33.898496+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}